Proton therapy

American Shared Hospital Services Signs Office Sub-Lease

Tuesday, November 30, 2021 - 1:00pm

SAN FRANCISCO, CA, Nov. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company has signed a sub-lease for its existing corporate offices. AMS has also signed a lease for new corporate offices with a smaller footprint.

Key Points: 
  • SAN FRANCISCO, CA, Nov. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company has signed a sub-lease for its existing corporate offices.
  • AMS has also signed a lease for new corporate offices with a smaller footprint.
  • As a consequence, the Company has sublet its current corporate office and will relocate its corporate office to a smaller space at 601 Montgomery Street, Suite 1112, San Francisco, California on December 1, 2021.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain).The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems.

Hitachi Selected by the University of Tsukuba for its Second Proton Therapy System as a PFI Project

Monday, November 22, 2021 - 4:57am

The new proton therapy center will be equipped with Hitachi's compact design proton therapy system, including a set of one accelerator and two rotating gantry treatment rooms.

Key Points: 
  • The new proton therapy center will be equipped with Hitachi's compact design proton therapy system, including a set of one accelerator and two rotating gantry treatment rooms.
  • Image of New Proton Therapy Center; The new center is on the left of existing site
    The University of Tsukuba has been using Hitachi's proton therapy system since 2001.
  • Upon completion and opening of the new proton therapy center, the University of Tsukuba will shift its treatment from the existing center to the new center.
  • In 2001, the University of Tsukuba adopted Hitachi's proton therapy system and has provided proton therapy to approximately 6,000 cancer patients to date.

NorthStar Medical Radioisotopes and IBA Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Therapeutic Radioisotope Actinium-225 (Ac-225)

Thursday, November 18, 2021 - 1:00pm

actinium-225 (Ac-225), an important therapeutic radioisotope that is in highly limited supply and for which no commercial-scale production technology currently exists.

Key Points: 
  • actinium-225 (Ac-225), an important therapeutic radioisotope that is in highly limited supply and for which no commercial-scale production technology currently exists.
  • NorthStar previously purchased two Rhodotron accelerators from IBA for its newly completed molybdenum-99 (Mo-99) production facility.
  • NorthStar is at the forefront of U.S. radioisotope production as the only commercialized producer of the diagnostic imaging radioisotope molybdenum-99 (Mo-99).
  • Using first-in-kind and environmentally-sound electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu-67).

American Shared Hospital Services Reports Third Quarter 2021 Financial Results

Wednesday, November 10, 2021 - 1:00pm

SAN FRANCISCO, CA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the third quarter of 2021, ended September 30, 2021.

Key Points: 
  • SAN FRANCISCO, CA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the third quarter of 2021, ended September 30, 2021.
  • Revenue for the Company's Gamma Knife operations decreased 5.9% to $2,806,000 for the third quarter of 2021 compared to $2,983,000 for the third quarter of 2020.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,562,000 for the third quarter of 2021, compared to $1,979,000 for the third quarter of 2020.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.

American Shared Hospital Services Announces Third Quarter 2021 Earnings Conference Call

Wednesday, November 3, 2021 - 12:00pm

San Francisco, CA, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2021 financial results on Wednesday, November 10, 2021 at 3:00pm EST / 12:00pm PST. The third quarter 2021 financial results press release will be issued premarket the morning of Wednesday, November 10, 2021.

Key Points: 
  • San Francisco, CA, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2021 financial results on Wednesday, November 10, 2021 at 3:00pm EST / 12:00pm PST.
  • The third quarter 2021 financial results press release will be issued premarket the morning of Wednesday, November 10, 2021.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.

Best Medical International & TeamBest Global Will Exhibit at ASTRO 2022 Meeting in San Antonio, Texas on October 23–26

Tuesday, October 26, 2021 - 9:36pm

Best Medical International (BMI) & TeamBest Global Companies (TBG) are announcing they will be exhibiting at the 2022 ASTRO Meeting that will be held in San Antonio, Texas, October 2326.

Key Points: 
  • Best Medical International (BMI) & TeamBest Global Companies (TBG) are announcing they will be exhibiting at the 2022 ASTRO Meeting that will be held in San Antonio, Texas, October 2326.
  • In addition, BMI will introduce Proton Therapy Cyclotrons up to 150 MeV and 400 MeV ion Rapid Cycling Medical Synchrotrons (iRCMS) for Proton-to-Carbon Heavy Ion High Precision Radiation Therapy.
  • Best Medical International & TeamBest Global Companies' booth floorplan layout is approximately 5000 sq.
  • ft. and will be positioned near the entrance of the ASTRO 2022 exhibit space in San Antonio, Texas.

RaySearch and IBA expand their partnership in proton therapy

Tuesday, October 26, 2021 - 4:30pm

STOCKHOLM, Oct. 26, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) and IBA announce that they expand their partnership in proton therapy within the areas of FLASH radiotherapy, proton ARC therapy, and treatment of moving tumors.

Key Points: 
  • STOCKHOLM, Oct. 26, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) and IBA announce that they expand their partnership in proton therapy within the areas of FLASH radiotherapy, proton ARC therapy, and treatment of moving tumors.
  • RaySearch and IBA have had a strategic partnership on a global level since 2013.
  • The result will be a turnkey solution for all software and hardware needed to deliver outstanding proton therapy treatments.
  • Johan Lf, founder and CEO, RaySearch, says: "Today the combination of RaySearch's RayStation and IBA's Proteus is an industry standard within proton therapy.

Mevion Selected to Equip Compact Proton Therapy Center in Kansas City

Monday, October 25, 2021 - 12:00pm

The size and cost of larger proton technologies has been a major impediment to the adoption of proton therapy.

Key Points: 
  • The size and cost of larger proton technologies has been a major impediment to the adoption of proton therapy.
  • Today, new proton therapy centers in the US are almost exclusively compact single-room systems and Mevion is the preferred compact provider in the US.
  • Kansas City Urology Care is the premier center for urology care in Kansas City that assures cutting-edge treatment solutions for all forms of urological conditions.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

Sumitomo Heavy Industries Succeeds in Developing a Superconducting Cyclotron for Proton Therapy

Monday, October 25, 2021 - 7:00am

Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (President: Shinji Shimomura, hereinafter referred to as "SHI") has conducted proton beam acceleration tests on its in-house developed superconducting cyclotron for the next-generation proton therapy system under development and confirmed the generation of a high-intensity proton beam of 1,000 nA.

Key Points: 
  • Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (President: Shinji Shimomura, hereinafter referred to as "SHI") has conducted proton beam acceleration tests on its in-house developed superconducting cyclotron for the next-generation proton therapy system under development and confirmed the generation of a high-intensity proton beam of 1,000 nA.
  • The successful development of the superconducting cyclotron is a significant step toward realizing the next-generation proton therapy system being developed by SHI.
  • This time, SHI has succeeded in developing a superconducting cyclotron capable of generating a high-intensity proton beam of 1000 nA, the world's highest level for a proton therapy system.
  • SHI are aiming to widespread use of proton therapy by making proton therapy systems smaller and less expensive.

RaySearch and Mevion to develop next-generation treatment planning techniques for FLASH proton radiotherapy treatment

Friday, October 22, 2021 - 4:11pm

STOCKHOLM, Oct. 22, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) and Mevion Medical Systems, two companies that are leading the field of proton therapy, announce a collaboration to develop advanced treatment planning techniques for FLASH* delivery with the MEVION S250i Proton Therapy System.

Key Points: 
  • STOCKHOLM, Oct. 22, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) and Mevion Medical Systems, two companies that are leading the field of proton therapy, announce a collaboration to develop advanced treatment planning techniques for FLASH* delivery with the MEVION S250i Proton Therapy System.
  • Townsend Zwart, Vice President of Advanced Development, Mevion Medical Systems, says: "Mevion is pleased to continue our long partnership with RaySearch to develop ultra-high dose rate (FLASH) intensity modulated proton therapy.
  • Since 2014, RaySearch and Mevion have collaborated to provide advanced treatment planning capabilities for Mevion's HYPERSCAN pencil-beam scanning and Adaptive Aperture pMLC.
  • RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.